Article
Pharmacology & Pharmacy
Tianrong Xun, Yan Rong, Bin Lv, Jinfei Tian, Qing Zhang, Xixiao Yang
Summary: This study aimed to investigate the pharmacokinetic interactions and potential mechanisms between atorvastatin (ATO) and voriconazole (VOR). Results from patient and rat models showed that VOR significantly reduced the metabolism of ATO and slowed the formation of its metabolites. In vitro studies demonstrated that VOR inhibited the metabolism of ATO and testosterone. These findings are important for dose adjustment and the design of rational treatment regimens for fungal infections in patients with dyslipidemia.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Chemistry, Medicinal
Jae Hoon Kim, Jung Sunwoo, Ji Hye Song, Yu-Bin Seo, Won Tae Jung, Kyu-Yeol Nam, YeSeul Kim, Hye Jung Lee, JungHa Moon, Jin-Gyu Jung, Jang Hee Hong
Summary: The interaction between atorvastatin and omega-3 fatty acids was evaluated in a phase 1 trial, and it was found that co-administration of the two drugs affected their concentrations, indicating a drug-drug interaction.
Review
Food Science & Technology
Zvonimir Petric, Irena Zuntar, Predrag Putnik, Danijela Bursac Kovacevic
Summary: Fruit juices contain phytochemicals which can interfere with drug metabolism enzymes, leading to food-drug interactions that affect drug effects and toxicity. These interactions typically affect pharmacokinetic parameters, but predicting them accurately is challenging due to limited study subjects and individual variability.
Article
Biology
Izabela Zakrocka, Tomasz Kocki, Ewa Urbanska, Wojciech Zaluska
Summary: Kidney dysfunction significantly increases cardiovascular risk, and hypertriglyceridemia is a common lipid abnormality in kidney disorders. This study aimed to analyze the effect of commonly used triglyceride-lowering drugs on KYNA production and enzyme activity in rat kidneys. The results showed that these drugs inhibited KYNA synthesis and affected specific enzyme activity, suggesting their potential role in kidney function protection.
Article
Multidisciplinary Sciences
Yan Ding, Huida Guan, Yingxuan Yan, Yan Chen, Cheng Huang
Summary: This study aimed to investigate the drug-drug interaction (DDI) of Nomilin (Nom) and Atorvastatin (Atv) in vivo. The pharmacokinetic and pharmacodynamic studies revealed that Nom can impact the pharmacokinetic profile and pharmacodynamic effect of Atv, leading to a lesser reduction in lipid levels of mice treated with the combination of Nom and Atv. Furthermore, Nom can increase the activity and expression levels of hepatic microsomal CYP3A11.
Review
Biochemistry & Molecular Biology
Manish B. Shah
Summary: The acyl glucuronide metabolites of gemfibrozil and clopidogrel can selectively inhibit the enzyme CYP2C8, leading to clinically important drug-drug interactions. Understanding the binding and orientation of these metabolites in the active site of CYP2C8 is crucial for further research and application.
Article
Biochemistry & Molecular Biology
Yanjun Cui, Ying Li, Caihui Guo, Yajing Li, Yinling Ma, Zhanjun Dong
Summary: This study investigated the pharmacokinetic drug interactions between canagliflozin and sorafenib or lenvatinib and found significant changes in the plasma concentrations and apparent clearance of these drugs. These findings provide a reference for the use of canagliflozin, sorafenib and lenvatinib in patients with HCC and T2DM.
Review
Chemistry, Medicinal
Jie Li, Shuting Wang, Fengjie Tian, Shuang-Qing Zhang, Hongtao Jin
Summary: As the use of herbs increases worldwide, there are more reports of interactions between herbs and drugs. The complex active components of herbs inevitably affect the pharmacokinetics of chemical drugs in vivo. The expression of drug transporters is closely related to the absorption, distribution, metabolism, and excretion of drugs. When herbs inhibit or induce the expression of transporters, it can result in changes in substrate pharmacokinetics, affecting the efficacy and toxicity of drugs. This article summarizes the tissue distribution and physiological functions of drug transporters, analyzes the effects of herbs on drug transporters, and discusses the possible mechanisms of herb-drug interactions, providing ideas and references for safe clinical drug use.
Article
Chemistry, Medicinal
Moon Hee Lee, Seok-Kyu Yoon, Hyungsub Kim, Yong-Soon Cho, Sungpil Han, Shi Hyang Lee, Kyun-Seop Bae, Jina Jung, Sung Hee Hong, Hyeong-Seok Lim
Summary: This study aimed to examine the pharmacokinetic interactions between bazedoxifene and cholecalciferol and the tolerability of their combined administration in healthy male subjects. The results showed that this combined therapy was well tolerated at the dose levels used in the study, and there was a mild degree of pharmacokinetic interaction.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2023)
Article
Pharmacology & Pharmacy
Ruhul Kayesh, Vishakha Tambe, Chao Xu, Wei Yue
Summary: Impaired transport activity of hepatic OATP1B1 and OATP1B3 due to drug-drug interactions (DDIs) often leads to increased systemic exposure to substrate drugs. This study aimed to assess the OATP1B1- and OATP1B3-mediated DDI potential of the calcium channel blocker nicardipine. The results showed that nicardipine has the potential to cause OATP1B1/3-mediated DDIs, and the consideration of optimal preincubation conditions is important when assessing these interactions in vitro.
Review
Pharmacology & Pharmacy
Young Hee Choi, Young-Won Chin
Summary: Studies have shown that metabolic enzyme and/or transporter-mediated pharmacokinetic changes in a drug caused by concomitant herbal products may affect efficacy and toxicity, but discrepancies between predictive data and clinical significance still exist, adding to confusion regarding the use of herbal products and drug combinations.
Review
Oncology
Stefano Fogli, Giulia Gianfilippo, Federico Cucchiara, Marzia Del Re, Laura Valerio, Rossella Elisei, Romano Danesi
Summary: Lenvatinib is a non-selective tyrosine kinase inhibitor that is most effective in patients with thyroid cancer. The drug is well tolerated and common adverse reactions can be managed by dose adjustment. Monitoring of blood pressure and cardiac function may be required during treatment.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2021)
Review
Pharmacology & Pharmacy
Nicola Ferri, Elisa Colombo, Marco Tenconi, Ludovico Baldessin, Alberto Corsini
Summary: Direct oral anticoagulants (DOACs) are frequently prescribed to prevent ischemic stroke in non-valvular atrial fibrillation (NVAF) patients and treat venous thromboembolism (VTE). They have a favorable risk-benefit profile compared to warfarin but may increase the risk of gastrointestinal bleeding. Polypharmacy and comorbidity in elderly patients can lead to drug-drug interactions (DDIs) with DOACs. This review summarizes potential DDIs and discusses strategies to reduce their occurrence.
Article
Pharmacology & Pharmacy
Sejung Hwang, Jae-Wook Ko, Heechan Lee, Seokuee Kim, Bongtae Kim, Geun Seog Song, Jungryul Kim
Summary: In healthy subjects, after multiple doses, co-administration of atorvastatin with vonoprazan increased systemic exposure of atorvastatin and the incidence of hypergastrinemia. However, these interactions were not observed when atorvastatin was co-administered with tegoprazan.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Chemistry, Medicinal
Wonsuk Shin, A-Young Yang, Hyounggyoon Yoo, Anhye Kim
Summary: Combining tamsulosin and mirabegron has shown no clinically relevant drug interactions in terms of pharmacokinetics, safety, and tolerability. The combination increases tamsulosin exposure in plasma while reducing the maximum plasma concentration of mirabegron.